Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides

Journal of Drugs in Dermatologyμg/kg weekly) plus psoralen with UVA (PUVA) versus IFN-α-2b (9 MIU 3×/week) plus PUVA.3An open label pilot study was conducted between 2008-2011 in patients with advanced stage MF/SS (stage IIB-IVB) who had ECOG ≤1 and no previous interferon therapy.Five patients with MF [IIB (4/7), IIIB (1/7)] and 2 with Sézary Syndrome (SS) were enrolled with a median age of 58 years (range, 38-79) (Table1).They received PEG-IFN-α-2b at a starting dose of 1.5 µg/kg, administered subcutaneously once weekly with dose escalation up to 9 µg/kg or maximum tolerated dose.PUVA treatment or narrow-band UVB was scheduled three times weekly following the institutional standard protocol.